Literature DB >> 16638500

Pattern of increased cerebral FDG uptake in Down syndrome patients.

Zsolt Lengyel1, Erzsébet Balogh, Miklós Emri, Edit Szikszai, József Kollár, Judit Sikula, Olga Esik, Lajos Trón, Eva Oláh.   

Abstract

Resting cerebral glucose metabolism was assessed by 18[F]-fluorodeoxyglucose in 11 Down syndrome patients. Standardized uptake values were determined on a pixel-by-pixel basis from the measured tissue-activity data. The results revealed a mean overall 18[F]-fluorodeoxyglucose uptake in the Down syndrome patients close to that observed in the control group, consisting of children and young adults. However, the standard deviation of the standardized uptake values was much higher in the Down syndrome group in almost all voxels relating to the gray matter. The statistical parametric mapping method was applied to compare the cerebral 18[F]-fluorodeoxyglucose accumulation patterns of the Down syndrome and control groups. Six regions (clusters) were found for which the glucose uptake was higher in the Down syndrome patients than in the control group. The anatomic localization of these clusters was based on magnetic resonance investigations and a brain-atlas technique. The localization of the identified clusters with an increased glucose metabolism in the Down syndrome patients suggests that these subjects have an enhanced resting neuronal activity in cortical areas involved in reasoning, cognition, and speech as compared with normal subjects.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16638500     DOI: 10.1016/j.pediatrneurol.2005.08.035

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  6 in total

1.  Positron emission tomography and neuropathologic estimates of fibrillar amyloid-β in a patient with Down syndrome and Alzheimer disease.

Authors:  Marwan N Sabbagh; Adam Fleisher; Kewei Chen; Joseph Rogers; Camryn Berk; Eric Reiman; Michael Pontecorvo; Mark Mintun; Daniel Skovronsky; Sandra A Jacobson; Lucia I Sue; Carolyn Liebsack; Albert S Charney; Lauren Cole; Christine Belden; Thomas G Beach
Journal:  Arch Neurol       Date:  2011-11

Review 2.  Alzheimer's disease associated with Down syndrome: a genetic form of dementia.

Authors:  Juan Fortea; Shahid H Zaman; Sigan Hartley; Michael S Rafii; Elizabeth Head; Maria Carmona-Iragui
Journal:  Lancet Neurol       Date:  2021-11       Impact factor: 59.935

Review 3.  Beyond amyloid: Immune, cerebrovascular, and metabolic contributions to Alzheimer disease in people with Down syndrome.

Authors:  Alessandra C Martini; Thomas J Gross; Elizabeth Head; Mark Mapstone
Journal:  Neuron       Date:  2022-04-25       Impact factor: 18.688

4.  Dissociation of Down syndrome and Alzheimer's disease effects with imaging.

Authors:  Dawn C Matthews; Ana S Lukic; Randolph D Andrews; Boris Marendic; James Brewer; Robert A Rissman; Lisa Mosconi; Stephen C Strother; Miles N Wernick; William C Mobley; Seth Ness; Mark E Schmidt; Michael S Rafii
Journal:  Alzheimers Dement (N Y)       Date:  2016-06

Review 5.  Metabolic and Vascular Imaging Biomarkers in Down Syndrome Provide Unique Insights Into Brain Aging and Alzheimer Disease Pathogenesis.

Authors:  Elizabeth Head; David K Powell; Frederick A Schmitt
Journal:  Front Aging Neurosci       Date:  2018-06-21       Impact factor: 5.750

Review 6.  From abnormal hippocampal synaptic plasticity in down syndrome mouse models to cognitive disability in down syndrome.

Authors:  Nathan Cramer; Zygmunt Galdzicki
Journal:  Neural Plast       Date:  2012-07-12       Impact factor: 3.599

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.